Hemophilia B Pipeline 2026 Report Highlights Next-Gen Gene Therapies, FDA Advances, And Clinical Momentum Across Novo Nordisk, Pfizer, Sanofi & Emerging Biotechs

DelveInsight's comprehensive report outlines the current Hemophilia B treatment landscape and future pipeline developments.

Apr. 9, 2026 at 10:08pm

Got story updates? Submit your updates here. ›

A highly detailed, translucent X-ray photograph revealing the complex internal structure of a human blood cell or clotting factor molecule, conceptually representing the advancements in Hemophilia B therapies.Cutting-edge gene therapies and FDA-approved treatments aim to transform the Hemophilia B treatment landscape, offering new hope for patients.Albany Today

DelveInsight's 'Hemophilia B Pipeline Insight, 2026' report provides a comprehensive analysis of the present clinical development scenario and growth prospects across the Hemophilia B market. The report highlights that globally, Hemophilia B pipeline constitutes 15+ key companies continuously working towards developing 20+ Hemophilia B treatment therapies, including next-generation gene therapies, FDA-approved advances, and clinical momentum across major pharmaceutical players and emerging biotechs.

Why it matters

Hemophilia B is a rare genetic bleeding disorder that affects the body's ability to properly clot blood. The Hemophilia B pipeline report outlines the significant progress being made in developing novel therapies to address the unmet needs of this patient population, including therapies that could potentially provide long-term treatment solutions and reduce the burden of frequent infusions.

The details

The report covers a detailed assessment of Hemophilia B therapies in various stages of clinical development, from pre-clinical to marketed stages. Key Hemophilia B pipeline therapies highlighted include BBM-H901, ISU304, TU7710, BE-101, REGV131, PF-06838435, ANB-002, AAV5-hFIXco-Padua, VGB-R04, AskBio009, AMA005, CB 2679d-GT, FLT180a, BBM-H901, SerpinPC, Concizumab, Fitusiran, and PF-06. The report also covers recent regulatory milestones, such as the FDA's priority review and approval of therapies like Hemgenix and Alhemo for Hemophilia B patients.

  • In February 2026, Pfizer's supplemental Biologics License Application (sBLA) for HYMPAVZI was accepted and granted Priority Review by the FDA.
  • In January 2026, end-of-study results from the pivotal Phase 3 HOPE-B clinical trial for CSL Behring and uniQure's Hemgenix were presented at the ASH Annual Meeting.
  • In September 2025, Pfizer announced a long-term safety and efficacy follow-up study for Hemophilia B patients previously enrolled in the C0371005 trial.
  • In August 2025, Concizumab-mtci (Alhemo®) was approved by the US FDA as the first once-daily subcutaneous prophylactic therapy for Hemophilia A or B patients without inhibitors.
  • In July 2025, Novo Nordisk's Alhemo® (concizumab-mtci) was approved by the FDA for prophylactic use in Hemophilia A or B patients aged 12 and older without inhibitors.

The players

Belief Biomed

A biopharmaceutical company developing novel gene therapies, including the Hemophilia B candidate BBM-H901.

Pfizer

A global pharmaceutical company with several Hemophilia B therapies in its pipeline, including PF-06838435 and PF-06741086.

CSL Behring

A global biotherapeutics company that developed and markets the FDA-approved Hemophilia B gene therapy Hemgenix.

Novo Nordisk

A leading pharmaceutical company that received FDA approval for its Hemophilia A/B therapy Alhemo® (concizumab-mtci).

Sanofi

A multinational pharmaceutical company with the Hemophilia B therapy Fitusiran in its pipeline.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

The Hemophilia B pipeline report highlights the significant advancements being made in developing innovative therapies, including next-generation gene therapies and FDA-approved treatments, that have the potential to transform the standard of care and improve outcomes for patients living with this rare genetic disorder.